Tumor of uterus
MONDO:0021353A neoplasm (disease) that involves the uterus.
Also known as: neoplasm of the uterus, neoplasm of uterus, tumor of the uterus, tumor of uterus, tumour of the uterus, uterine neoplasm, uterine neoplasms, uterine tumor
2470 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Custom-Made cancer vaccine tested in 25 patients
⭐️ VACCINE ⭐️ CompletedThis study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.
Phase: PHASE1 • Sponsor: Aaron Miller • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:00 UTC
-
Could a vaccine stop cervical cancer from coming back?
⭐️ VACCINE ⭐️ CompletedThis early study tested the safety of a vaccine called TA-CIN in 15 people who had been treated for HPV16-related cervical cancer. The goal was to see if the vaccine could help the immune system fight any remaining cancer cells and prevent the cancer from returning. Participants …
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
-
Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
Disease control CompletedThis study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase: PHASE1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Which radiotherapy technique offers best value for pelvic cancers?
Disease control CompletedThis trial compares three modern radiotherapy techniques—helical tomotherapy and two types of dynamic arc therapy (RapidArc and VMAT)—for treating prostate, cervical, and anal canal cancers that require pelvic lymph node irradiation. The goal is to determine which method is most …
Phase: NA • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising combo tackles tough cancers in early trial
Disease control CompletedThis early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Triple immunotherapy attack shows promise against Hard-to-Treat HPV cancers
Disease control CompletedThis study tests a combination of three immunotherapy drugs—PDS0101, M7824, and NHS-IL12—in people with advanced HPV-related cancers such as cervical, anal, and throat cancers. The goal is to see if the mix can shrink tumors or stop them from growing. Participants receive the dru…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a Low-Carb diet help fight endometrial cancer?
Disease control CompletedThis study looks at whether a ketogenic diet—a very low-carbohydrate diet that forces the body to burn fat for energy—is safe and tolerable for overweight or obese women with newly diagnosed endometrial cancer before they have surgery. Nineteen participants will either follow the…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a targeted drug shrink advanced cervical tumors?
Disease control CompletedThis phase 2 trial tests the drug cabozantinib in women with advanced or metastatic cervical cancer that has worsened after platinum-based chemotherapy. The study aims to see if cabozantinib can control the disease and how safe it is, particularly regarding risks like fistulas. P…
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cancer drug combo tested in early human trial
Disease control CompletedThis early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…
Phase: PHASE1 • Sponsor: ImmunOs Therapeutics AG • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental DNA vaccine targets HPV to fight precancerous cervical cells
Disease control CompletedThis early-stage trial tested a DNA vaccine called NWRD08 in 9 women with high-grade cervical lesions caused by HPV types 16 or 18. The vaccine was given as a shot followed by a mild electrical pulse to help cells take it up. The main goal was to check safety and see if the vacci…
Phase: PHASE1 • Sponsor: Newish Technology (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail targets Hard-to-Treat ovarian and endometrial cancers
Disease control CompletedThis early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Heated chemo during surgery may curb return of rare uterine cancer
Disease control CompletedThis phase 2 trial tested whether giving heated chemotherapy directly into the abdomen during surgery, followed by standard chemo, could help prevent uterine leiomyosarcoma from coming back. Seventeen women with locally recurrent cancer took part. The goal was to see if this comb…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug IBI129 tested in humans for first time against Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase: PHASE1, PHASE2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Timing matters: early platelet booster may prevent dangerous drops in cervical cancer treatment
Disease control CompletedThis study looked at when to start giving a drug called rhTPO to cervical cancer patients whose platelet levels drop during chemoradiation. The goal was to see if starting treatment earlier could prevent severe low platelet counts. Researchers studied 75 patients and compared two…
Phase: NA • Sponsor: Mei Feng • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in helping immune system fight advanced cancers
Disease control CompletedThis study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase: PHASE1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for advanced endometrial cancer: immunotherapy combo trial shows promise
Disease control CompletedThis phase 2 study tested a drug called retifanlimab, which helps the immune system attack cancer, either alone or combined with other targeted drugs. It enrolled 206 women with advanced or metastatic endometrial cancer that had worsened after platinum-based chemotherapy. The goa…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cocktail of three drugs tested for tough bladder cancers
Disease control CompletedThis early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to shrink fibroids in pregnant women
Disease control CompletedThis study tested a drug called SB-UF, which combines hormones and a plant extract, to see if it can shrink uterine fibroids in pregnant women. 66 women took the drug or a placebo throughout their pregnancy. The goal was to reduce fibroid size and help them disappear, which could…
Phase: PHASE4 • Sponsor: Trieu, Nguyen Thi, M.D. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New adaptive radiotherapy aims to shrink treatment margins for uterine cancers
Disease control CompletedThis study tested a new type of radiation therapy that adjusts the treatment plan daily based on the patient's anatomy. It included 15 women with endometrial or cervical cancer who had surgery and needed radiation. The goal was to see if smaller treatment margins could be used sa…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New shot form of cancer drug tested in 142 patients
Disease control CompletedThis study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Minimally invasive surgery vs. open surgery for cervical cancer: which is better?
Disease control CompletedThis study compared two surgical approaches for early-stage cervical cancer: laparoscopic-assisted (minimally invasive) and open abdominal hysterectomy. Sixty women with stage IA1 to IB1 cervical cancer were randomly assigned to one of the two surgeries. Researchers measured surg…
Phase: NA • Sponsor: Zagazig University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Major trial tests if abdominal chemo beats IV for tough cancers
Disease control CompletedThis large Phase III trial tested whether adding the drug bevacizumab to chemotherapy works better when the chemo is given into a vein (IV) or directly into the belly (IP). It involved 1560 people with advanced ovarian, fallopian tube, or peritoneal cancers. The goal was to see w…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New HIV vaccine and antibody cocktail aims to free patients from daily meds
Disease control CompletedThis study tested a two-part vaccine (Ad26.Mos4.HIV and MVA-BN-HIV) combined with three broadly neutralizing antibodies (PGT121, PGDM1400, VRC07-523LS) in 28 adults with HIV who were already on suppressive antiretroviral therapy (ART). The goal was to see if this combination coul…
Phase: PHASE1, PHASE2 • Sponsor: Boris Juelg, MD PhD • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug XTX202 tested in patients with advanced cancers
Disease control CompletedThis study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to tackle childhood cancers that Won't quit
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…
Phase: PHASE1 • Sponsor: Peter Zage • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cocktail of three drugs shows promise for Tough-to-Treat uterine cancer
Disease control CompletedThis early-phase trial tested a combination of three drugs—olaparib, metformin, and cyclophosphamide—in 35 women with recurrent advanced endometrial cancer that had already been treated with chemotherapy. The goal was to find a safe dose and see if the combination could stop the …
Phase: PHASE1, PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo tested for tough cancers
Disease control CompletedThis early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could a third chemo drug tame advanced endometrial cancer?
Disease control CompletedThis study looked at whether adding a drug called epirubicin to the standard two-drug chemotherapy (paclitaxel and carboplatin) helps people with advanced endometrial cancer. Sixty patients were enrolled to see if the three-drug combo is better at controlling the disease before s…
Phase: NA • Sponsor: Sohag University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…
Phase: PHASE1, PHASE2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New birth control pill aims to help women with painful conditions
Disease control CompletedThis study tested whether a daily combination pill (relugolix, estradiol, and norethindrone acetate) can prevent pregnancy in women aged 18 to 50 who have uterine fibroids or endometriosis. Over 1,100 women took the pill for up to a year, and researchers counted how many became p…
Phase: PHASE3 • Sponsor: Sumitomo Pharma Switzerland GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental cancer drug injected directly into tumors shows early promise
Disease control CompletedThis early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug KL340399 tested in 21 patients
Disease control CompletedThis early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Targeted pill shows promise for rare genetic tumor types
Disease control CompletedThis phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cancer drug HBM1020 tested in tiny early trial
Disease control CompletedThis early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…
Phase: PHASE1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control CompletedThis study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase: PHASE1, PHASE2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control CompletedThis phase II trial tested whether combining two drugs, pembrolizumab and olaparib, could help people with persistent or recurrent endometrial cancer or carcinosarcoma. The study enrolled 26 participants and looked at how many responded to treatment and what side effects occurred…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental antibody HH-101 tested in 12 patients with advanced cancers
Disease control CompletedThis early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Immunotherapy combo shows promise in advanced cervical cancer trial
Disease control CompletedThis phase 3 trial tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and bevacizumab helps women with advanced, persistent, or recurrent cervical cancer live longer. The study enrolled 410 participants and compared the new combination against the …
Phase: PHASE3 • Sponsor: Grupo Español de Investigación en Cáncer de Ovario • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control CompletedThis completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug shows promise in early trial for Tough-to-Treat tumors
Disease control CompletedThis study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…
Phase: PHASE1, PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug tested for advanced cancers: early results
Disease control CompletedThis early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…
Phase: PHASE1 • Sponsor: Idience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Engineered immune cells take on HPV cancers in early trial
Disease control CompletedThis study tested a new experimental treatment called HPVST cells in 32 people with HPV-related cancers that had returned or not responded to standard care. The cells are grown from the patient's own blood and trained to attack HPV-infected cancer cells. The goal was to find a sa…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New Double-Action antibody shows promise against Hard-to-Treat cancers
Disease control CompletedThis phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New pill aims to keep endometrial cancer at bay after chemo
Disease control CompletedThis Phase 3 trial tested whether taking the drug selinexor as a maintenance pill after chemotherapy can help delay cancer progression in people with advanced or recurrent endometrial cancer. 263 participants who had responded to initial chemo were randomly assigned to receive ei…
Phase: PHASE3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail shows promise for Tough-to-Treat uterine cancer
Disease control CompletedThis phase 2 trial tested a combination of three drugs—rucaparib, bevacizumab, and atezolizumab—in 30 people with recurrent or progressive endometrial cancer that had not responded to prior treatments. The goal was to see if the combination could shrink tumors or slow the cancer'…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
E-Cigarettes vs. patches: which helps women with cervical dysplasia quit smoking?
Disease control CompletedThis study tested two ways to help women with cervical dysplasia stop smoking: nicotine patches, gum, or lozenges versus electronic cigarettes. Thirty-one women participated for six weeks. The goal was to see if these methods are acceptable and help reduce or stop smoking. It was…
Phase: NA • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New Antibody-Drug conjugate STRO-002 tested in advanced cancers
Disease control CompletedThis study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deli…
Phase: PHASE1, PHASE2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Triple-Drug immunotherapy cocktail shows promise in advanced tumors
Disease control CompletedThis early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for Hard-to-Treat cancers? utidelone trial underway
Disease control CompletedThis phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…
Phase: PHASE2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Triple immunotherapy cocktail shows promise against tough cancers
Disease control CompletedThis study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Immunotherapy combo shows promise in cervical cancer trial
Disease control CompletedThis phase 2 trial tested whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with locally advanced cervical cancer. 189 participants received either the combination or standard treatment alone. The goal was to see if the combination delays …
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Diabetes drug plus chemo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Early trial checks safety of experimental cancer drug
Disease control CompletedThis early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise against advanced cancers in early trial
Disease control CompletedThis study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Diabetes drug metformin may boost chemo for ovarian cancer
Disease control CompletedThis phase II trial tested whether adding metformin, a common diabetes drug, to standard chemotherapy could help control advanced ovarian, fallopian tube, or primary peritoneal cancer. 111 participants received either metformin or a placebo alongside chemotherapy, followed by mai…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a pill keep endometrial cancer at bay? new study tests rucaparib
Disease control CompletedThis study tested whether the drug rucaparib can help keep metastatic or recurrent endometrial cancer from growing. 79 women who had already received chemotherapy took either rucaparib or a placebo pill twice daily. The goal was to see if rucaparib could delay cancer progression …
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Generic cancer pill matches Brand-Name drug in study
Disease control CompletedThis study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…
Phase: NA • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cancer drug ZN-c3 shows early promise in solid tumor trial
Disease control CompletedThis early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…
Phase: PHASE1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy shows promise for advanced uterine cancer
Disease control CompletedThis study tested a combination of two drugs, lenvatinib and pembrolizumab, against standard chemotherapy in 827 people with advanced endometrial cancer that had worsened after initial treatment. The goal was to see if the combo could delay cancer growth and extend life. Results …
Phase: PHASE3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New immunotherapy combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis phase 2 trial tested a combination of two drugs, favezelimab and pembrolizumab (MK-4280A), in 163 people with either a type of skin cancer (cutaneous squamous cell carcinoma) or endometrial cancer. The goal was to see if the treatment could shrink or eliminate tumors. The st…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control CompletedThis study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for women with Hard-to-Treat uterine cancer?
Disease control CompletedThis study tested an experimental drug called ZN-c3 (azenosertib) in 92 women with a rare and aggressive type of uterine cancer that had come back or not responded to standard treatments. The goal was to see if the drug could shrink tumors and to check its safety. The drug is tak…
Phase: PHASE2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New pill takes on stomach cancer in first human trial
Disease control CompletedThis study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shr…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug cocktail shows promise for Hormone-Sensitive uterine cancer
Disease control CompletedThis phase 2 study tested a combination of two drugs, fulvestrant and abemaciclib, in 28 patients with a specific type of uterine cancer that is sensitive to hormones. The goal was to see if the drugs could shrink tumors or stop them from growing. Researchers also tracked side ef…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New cancer combo drug tested in tiny safety study
Disease control CompletedThis early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body h…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Drug holiday or not? sarcoma study tests best strategy
Disease control CompletedThis study looked at 53 adults with advanced soft tissue sarcoma who had stable disease or improvement after 6 cycles of trabectedin. Half continued the drug, while the other half took a break (drug holiday). The goal was to see which approach better delays cancer progression and…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New cancer drug RS-0139 tested in humans for first time
Disease control CompletedThis early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…
Phase: PHASE1 • Sponsor: RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for advanced cervical cancer: immune combo shows promise
Disease control CompletedThis study tested a new drug combination (tiragolumab plus atezolizumab) against atezolizumab alone in 172 people with advanced or returning cervical cancer that has a specific marker (PD-L1-positive). The goal was to see if the combination could shrink tumors better. Participant…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Two-Drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy shows promise for Tough-to-Treat cervical cancer
Disease control CompletedThis study tested a combination of an immunotherapy drug (anti-PD-1) and a chemotherapy drug (albumin-bound paclitaxel) in 27 people whose cervical cancer had returned or worsened after standard treatment. The goal was to see if the combination could shrink tumors and help patien…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on HPV cancers
Disease control CompletedThis trial tested a new therapy for cancers caused by HPV-16, such as cervical, anal, and throat cancers. Researchers took patients' white blood cells, genetically engineered them to recognize a protein called E7 found in HPV cancer cells, and infused them back. Patients also rec…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase: PHASE1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested the safety of combining two drugs—AZD1775 (a pill) and durvalumab (an IV infusion)—in 56 adults with advanced solid tumours that had stopped responding to standard treatments. The goal was to find safe doses and watch for side effects. While not a cu…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New shot aims to stop Chemo's dangerous side effect
Disease control CompletedThis early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New targeted pill shows promise for Hard-to-Treat bile duct cancers
Disease control CompletedThis study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug shows promise in battle against advanced cervical cancer
Disease control CompletedThis study tested whether a new drug called tisotumab vedotin works better than standard chemotherapy for people with cervical cancer that has spread or returned. Over 500 participants were randomly assigned to receive either the new drug or one of five chemotherapy options. The …
Phase: PHASE3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
MRI-Guided radiation may improve cervical cancer treatment
Disease control CompletedThis large phase III trial tested whether using MRI scans to guide internal radiation (brachytherapy) works better than the traditional X-ray method for women with locally advanced cervical cancer. Over 1,000 participants received either MRI-based or X-ray-based brachytherapy. Th…
Phase: NA • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could an HIV drug boost cervical cancer treatment?
Disease control CompletedThis study tested whether adding the HIV drug nelfinavir to standard chemoradiation helps people with advanced cervical cancer stay cancer-free longer. About 348 adults with stage III cervical cancer took part. One group got standard treatment, and the other got nelfinavir before…
Phase: PHASE3 • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo shows promise in controlling advanced cancers
Disease control CompletedThis study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Immunotherapy boosts standard treatment for advanced cervical cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation helps people with high-risk, locally advanced cervical cancer live longer without their cancer growing. About 1,060 participants received either pembrolizumab or a placebo alongside t…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New pill targets brain tumors with IDH mutations
Disease control CompletedThis early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could a cream after surgery stop cervical cancer in HIV-Positive women?
Disease control CompletedThis study looked at whether using an anti-cancer cream (5-fluorouracil) in the vagina after surgery is an acceptable and feasible way to treat cervical precancer in 180 South African women living with HIV. The goal was to see if women would stick with the treatment and find it a…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug AMG 305 tested in patients with advanced cancers
Disease control CompletedThis early-phase study tested a new drug called AMG 305 in 37 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Participants received the drug and were mo…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for kids with resistant tumors? early trial tests CUDC-907
Disease control CompletedThis early-phase study tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) with cancers that had come back or stopped responding to treatment, including solid tumors, brain tumors, and lymphoma. The main goal was to find a safe dose and check for side ef…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New oral drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose f…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New pill targets rare gene in Hard-to-Treat cancers
Disease control CompletedThis study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called RP-6306 in 28 people with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also looked for specific biomarkers to see if some patients respond bett…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New radiation technique may spare bowel in cervical cancer treatment
Disease control CompletedThis phase 3 trial tested whether a newer, more precise type of radiation (image-guided intensity modulated radiotherapy) could reduce long-term bowel problems compared to standard radiation in 300 women who had surgery for cervical cancer. The study focused on lowering severe bo…
Phase: PHASE3 • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cancer pill tested in humans for first time
Disease control CompletedThis early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…
Phase: PHASE1 • Sponsor: Godavari Biorefineries Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug duo shows promise against tough uterine cancer
Disease control CompletedThis phase 3 study tested whether combining the immunotherapy pembrolizumab with the targeted therapy lenvatinib works better than standard chemotherapy for women with advanced or recurrent endometrial cancer. Over 800 participants received either the drug combo or chemo. The goa…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Immunotherapy combo shows promise for advanced cervical cancer
Disease control CompletedThis phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps women with advanced cervical cancer live longer and keep the disease from growing. Over 600 women with persistent, recurrent, or metastatic cervical cancer took part. The …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New nanoparticle chemo shows promise in early trial for tough cancers
Disease control CompletedThis early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…
Phase: PHASE1 • Sponsor: SN BioScience • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…
Phase: PHASE1, PHASE2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
HPV vaccine shows promise in cutting cervical lesion risk for HIV-Positive women
Disease control CompletedThis study looked at whether the HPV vaccine can help prevent high-grade cervical lesions (precancerous growths) in women living with HIV who were already being treated for HPV. About 536 women took part, receiving either the HPV vaccine or a placebo. The goal was to see if the v…
Phase: PHASE3 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for tough cancers: revumenib trial shows promise
Disease control CompletedThis early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how th…
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat solid tumors
Disease control CompletedThis pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare …
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental immune therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells tha…
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Drug combo shows promise for tough cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…
Phase: PHASE1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered immune cells take aim at HPV-Positive cancers
Disease control CompletedThis early-stage trial tested a new type of cell therapy for people with HPV-positive head & neck or cervical cancer. The treatment uses a patient's own immune cells, engineered to recognize and attack HPV-infected cancer cells. Some patients also received cells that produce an a…
Phase: PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Chemo-Immuno cocktail shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…
Phase: PHASE1, PHASE2 • Sponsor: Kristoffer Rohrberg • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug shows promise for Hard-to-Treat cancers with p53 gene
Disease control CompletedThis study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …
Phase: PHASE1, PHASE2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug JAB-8263 tested in patients with advanced cancers
Disease control CompletedThis early-phase study tested a new drug called JAB-8263 in 41 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study is now complete.
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cancer drug MRX-2843 enters first human trial
Disease control CompletedThis early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…
Phase: PHASE1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental antibody combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called ADG116, which helps the immune system attack cancer cells. The study included 72 adults with advanced solid tumors that had stopped responding to standard treatments. Some participants received ADG116 alone, while others g…
Phase: PHASE1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Surgeons test safer way to remove oversized uteri without large cuts
Disease control CompletedThis study tested a new surgical method to remove very large uteri (over 20 weeks size) during total laparoscopic hysterectomy. The technique uses a cold knife to cut the uterus into a long strip that can be pulled out through the vagina, avoiding large abdominal incisions. Twent…
Phase: NA • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New immune booster FL115 tested in patients with advanced cancers
Disease control CompletedThis early-phase trial tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. FL115 is designed to strengthen the body's immune cells to fight cancer. The main goal was to check safety and find the right dose, wh…
Phase: PHASE1 • Sponsor: Suzhou Forlong Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The trial is no…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug IBI334 tested on 28 patients with advanced cancer
Disease control CompletedThis study tested a new drug called IBI334 in 28 people with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to check the drug's safety and see if it helps control the cancer. The study is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug ZGGS15 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…
Phase: PHASE1 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called JAB-BX102, alone or with the immunotherapy pembrolizumab, in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also …
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill shows promise in early trial for tough cancers
Disease control CompletedThis early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …
Phase: PHASE1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Heat and immune boost: new combo tackles Hard-to-Treat cancers
Disease control CompletedThis trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…
Phase: PHASE1, PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Cervical cancer trial: does extra chemo after surgery help?
Disease control CompletedThis phase 3 trial studied 236 women with high-risk early-stage cervical cancer who had already undergone a radical hysterectomy. Researchers compared standard chemoradiation (cisplatin plus pelvic radiation) with the same treatment followed by additional chemotherapy (paclitaxel…
Phase: PHASE3 • Sponsor: Radiation Therapy Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill JAB-3312 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New cancer pill shows promise in early trial
Disease control CompletedThis early-phase study tested a new oral drug called LP-118 in 68 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. LP-118 works by blocking two proteins that help cancer cells survive. The main goals were to find a safe dose and c…
Phase: PHASE1 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug NB003 tested in 258 patients with advanced cancers
Disease control CompletedThis early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…
Phase: PHASE1 • Sponsor: Ningbo Newbay Technology Development Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug RC88 shows promise for advanced cancers in early trial
Disease control CompletedThis study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.
Phase: PHASE1, PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New Tamoxifen-Like drug tested for stubborn hormone cancers
Disease control CompletedThis early-stage trial tested an experimental drug called Z-Endoxifen in 40 adults with hormone receptor-positive cancers (like breast, ovarian, or desmoid tumors) that had stopped responding to standard treatments. Z-Endoxifen is a direct form of tamoxifen's active ingredient, b…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill shows promise for Hard-to-Treat cancers in early trial
Disease control CompletedThis study tested a new drug called RP903 in 69 people with advanced solid tumors (like ovarian, breast, or cervical cancer) who had run out of standard options. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. It is an early-phase tria…
Phase: PHASE1 • Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and how the body processes it. Researchers looked for side effects and measured tumor respons…
Phase: PHASE1 • Sponsor: Ascletis Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New shorter radiation regimen tested for endometrial cancer
Disease control CompletedThis phase I study tested a shorter course of pelvic radiation (hypofractionated WPRT) in 8 patients with endometrial cancer after surgery. The goal was to see if this condensed schedule is safe and tolerable, focusing on side effects like bowel and bladder issues. The study is c…
Phase: NA • Sponsor: Teresa Meier • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New cancer drug shows promise in early human trial
Disease control CompletedThis early-stage trial tested a new oral drug, JNJ-64619178, in 114 people with advanced cancers (including solid tumors, lymphoma, and myelodysplastic syndromes) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effect…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo tested for advanced cancers in asian patients
Disease control CompletedThis early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…
Phase: EARLY_PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. While not a cure, the study…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug E7090 tested in patients with advanced solid tumors
Disease control CompletedThis early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for early signs of effectiveness, especially in patients whose tumors have certain…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New cancer drug ABBV-155 enters first human tests
Disease control CompletedThis early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Your own tumor cells could be the key to fighting cancer
Disease control CompletedThis early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is s…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New antibody drug tested in patients with Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called BAT6026 in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body …
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New cancer drug shows promise in early safety trial
Disease control CompletedThis early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New immunotherapy cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New combo therapy shows promise against tough uterine cancer
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab and lenvatinib, against standard chemotherapy for women with advanced or recurrent endometrial cancer. The goal was to see if the combo could slow cancer growth or improve survival better than chemo. The trial enrolled 1…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug duo shows early promise against advanced cancers
Disease control CompletedThis early-phase study tested a combination of two experimental drugs (AK127 and AK104) in 67 people with advanced or metastatic solid tumours that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for s…
Phase: EARLY_PHASE1 • Sponsor: Akesobio Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Gene-Edited immune cells take on Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new treatment called CTX131 for adults with advanced solid tumors that have not responded to standard therapies. The treatment uses donor immune cells that are gene-edited to target a protein called CD70 found on cancer cells. The study enrolled 19…
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New cancer drug GEN1056 tested in first human trial
Disease control CompletedThis early-stage trial tested a new drug, GEN1056, in 26 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked for signs that the drug might shrink tumors.
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New combo therapy for cervical cancer shows promise in early trial
Disease control CompletedThis phase 2 trial tested whether adding the targeted drug cetuximab to standard chemoradiation (cisplatin plus radiation) improves outcomes for people with locally advanced cervical cancer (stages IB2 to IIIB). 76 participants were randomly assigned to receive either chemoradiat…
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Fibroid treatment showdown: surgery or embolization for better baby chances?
Disease control CompletedThis study compared two treatments for symptomatic uterine fibroids—surgery (myomectomy) and a minimally invasive procedure (uterine artery embolization)—to see which one better helps women get pregnant and have a live birth. It included 9 women aged 18 to 43 with fibroids larger…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cancer drug BR101 enters first human tests
Disease control CompletedThis early-phase trial tested a new drug called BR101 in 15 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors. Participants receiv…
Phase: PHASE1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New immunotherapy combo shows promise for advanced cancers
Disease control CompletedThis study tested an experimental drug called BMS-986249, either alone or combined with the immunotherapy nivolumab (Opdivo), in 356 people with advanced solid tumors. The main goals were to check safety and find the right dose. Researchers also looked at whether the tumors shran…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New triple therapy shows promise for resistant cancers
Disease control CompletedThis early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …
Phase: PHASE1, PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Immunotherapy boosts standard treatment for aggressive cervical cancer
Disease control CompletedThis early-phase trial tested whether adding the immunotherapy drug atezolizumab before and during standard chemoradiation could help control advanced cervical cancer that has spread to lymph nodes. Forty participants received the combination to see if it activated the immune sys…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Early trial of BDB018 combo for tough cancers wraps up with just one patient
Disease control CompletedThis early-phase study tested a new immunotherapy drug called BDB018, given alone or with pembrolizumab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Only one person took part, …
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New antibody drug takes on Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can eribulin slow advanced cervical cancer? new trial results are in.
Disease control CompletedThis study tested a chemotherapy drug called eribulin in 32 people with advanced or recurrent cervical cancer that had spread or come back. The goal was to see how long the drug could keep the cancer from growing and to check for side effects. Participants had already received up…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug aims to boost immune system against tough cancers
Disease control CompletedThis early-phase trial tested a new drug called HCW9218 in 18 people with advanced solid tumors that had not responded to at least two prior treatments. The drug is designed to both activate immune cells and block signals that help tumors grow. The main goal was to find a safe do…
Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug tazemetostat gets Long-Term safety check in rollover trial
Disease control CompletedThis study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Could a custom vaccine help fight ovarian cancer?
Disease control CompletedThis early-phase trial tested a personalized vaccine made from a patient's own immune cells to see if it is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Nineteen participants who had already undergone surgery and chemotherapy received the vaccine. …
Phase: EARLY_PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
App helps young cancer survivors shed pounds
Disease control CompletedThis study tested a smartphone app to help young adult cancer survivors (ages 18-39) lose weight. The app tracked diet and activity as part of a behavioral weight loss program. The goal was to see if this approach was practical and well-liked by participants. The study involved 6…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New immunotherapy DF9001 targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…
Phase: PHASE1, PHASE2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Shorter radiation after hysterectomy shows promise for endometrial cancer
Disease control CompletedThis study tested a shorter course of pelvic radiation (about 1 week instead of the usual 5-6 weeks) given after hysterectomy for advanced endometrial cancer. The goal was to see if this shorter treatment causes fewer side effects while still controlling the cancer. The study inc…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including non-small cell lung cancer. The drug works by activating immune cells to fight cancer. The main goals were to check safety, find the best dose, and see how the drug move…
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New antibody combo tested in advanced cancer patients
Disease control CompletedThis early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and se…
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…
Phase: PHASE1 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage study tested a new drug (BI 836880) alone and with another drug (BI 754091) in 21 Japanese patients with advanced solid tumors. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling advanced…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug AMG 256 tested in patients with hard-to-treat cancers
Disease control CompletedThis early-phase study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that could not be cured by standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Researchers monitored side effects and how the…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug combo aims to boost immune system against Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental drug combo takes on tough cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to chec…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Which fibroid treatment is cheapest and safest? new study compares options
Disease control CompletedThis study looked at 114 women with symptomatic uterine fibroids who wanted to keep their uterus. It compared the costs and short-term safety of three procedures: radiofrequency ablation (Acessa), myomectomy (surgical removal of fibroids), and uterine artery embolization (blockin…
Phase: NA • Sponsor: Acessa Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Proton beam zaps liver tumors: new hope for cancer patients?
Disease control CompletedThis study tested a precise type of radiation called proton beam therapy for people whose cancer has spread to the liver. 92 adults with 1 to 4 liver tumors received this treatment. The goal was to see if it could stop tumor growth and cause fewer side effects than standard radia…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could a cancer drug shrink endometrial tumors?
Disease control CompletedThis phase 2 trial tested the drug cabozantinib in 102 women with endometrial cancer that had returned or spread. The drug works by blocking enzymes that help tumors grow and by cutting off their blood supply. Researchers measured how many patients saw their tumors shrink or stop…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase trial tested a new drug called BI 836880 in 24 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer drug shows early promise in small safety trial
Disease control CompletedThis early-phase trial tested a new drug called BI 836880 in 29 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to find a safe dose and check for side effects. The study was not designed to cure cancer, but to gather information …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer drug combo shows promise in early trial
Disease control CompletedThis early-phase trial tested two experimental drugs, BNT152 and BNT153, alone and together in 86 adults with advanced solid tumors that had spread or could not be removed and had no standard treatment options. The main goal was to check safety and find the best dose. Researchers…
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer cocktail shows promise in early human trial
Disease control CompletedThis early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Triple-Drug cocktail shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a combination of three drugs—selinexor, nivolumab, and ipilimumab—in 11 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The main goal was to check the safety and tolerability of the combination, whi…
Phase: PHASE1 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Immunotherapy combo shows promise in cervical cancer trial
Disease control CompletedThis early-phase study tested whether adding the immunotherapy drug nivolumab to standard chemoradiation is safe for people with locally advanced cervical cancer. Twenty-one adults received nivolumab alongside cisplatin and radiation, followed by up to six months of nivolumab alo…
Phase: PHASE1, PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 26, 2026 19:18 UTC
-
Immunotherapy combo shows promise for Hard-to-Treat ovarian cancer
Disease control CompletedThis phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 women with ovarian, fallopian tube, or peritoneal cancer that had come back or stopped responding to platinum-based chemotherapy. The study compared giving the drugs together versus one after …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 19:06 UTC
-
Immunotherapy combo shows promise for chinese cancer patients
Disease control CompletedThis study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients with advanced solid tumors that had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. The trial is now comple…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 17:18 UTC
-
New combo therapy targets Hard-to-Treat tumors
Disease control CompletedThis early-phase trial tested a new drug called RiMO-301, injected directly into tumors, along with standard radiation. It involved 32 people with advanced cancers that could not be cured. The main goal was to find a safe dose and check for any early signs of tumor shrinkage.
Phase: PHASE1 • Sponsor: Coordination Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:16 UTC
-
Diabetes drug may shield breast cancer patients from uterine thickening
Disease control CompletedThis study looked at whether metformin, a common diabetes drug, can reduce the thickening of the uterine lining caused by tamoxifen in postmenopausal breast cancer survivors. Sixty women who had been taking tamoxifen for at least a year were given either metformin or a placebo fo…
Phase: NA • Sponsor: Uruk University • Aim: Disease control
Last updated Jun 26, 2026 16:19 UTC
-
New pill plus immunotherapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…
Phase: PHASE1 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 15:48 UTC
-
New drug combo shows promise against resistant ovarian cancer
Disease control CompletedThis Phase 2 trial tested whether adding afuresertib (an AKT inhibitor) to standard paclitaxel chemotherapy helps control platinum-resistant ovarian cancer better than paclitaxel alone. 150 women with this difficult-to-treat cancer participated. The study measured how long the ca…
Phase: PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called LM-108, alone or combined with another immunotherapy, in 78 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers als…
Phase: PHASE1, PHASE2 • Sponsor: LaNova Australia Pty Limited • Aim: Disease control
Last updated Jun 26, 2026 15:31 UTC
-
New combo therapy shows promise for Hard-to-Treat cervical cancer
Disease control CompletedThis phase 2 study tested a combination of the immunotherapy drug cemiplimab and an HPV16-targeting vaccine (ISA101b) in 113 adults with recurrent or metastatic HPV16-positive cervical cancer that had progressed after first-line chemotherapy. The goal was to see if the combinatio…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 15:18 UTC
-
New radioactive therapy shows promise in early trial for tough cancers
Disease control CompletedThis early-phase trial tested a new radioactive drug called 177Lu-LNC1004 in 11 adults with advanced solid tumors that had stopped responding to standard treatments. The drug targets a protein (FAP) found on many cancer cells, delivering radiation directly to the tumor. The main …
Phase: PHASE1 • Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD. • Aim: Disease control
Last updated Jun 26, 2026 15:15 UTC
-
New cancer drug karonudib tested for first time in humans
Disease control CompletedThis early-phase trial tested a new drug, Karonudib, in 63 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body and any …
Phase: PHASE1 • Sponsor: Thomas Helleday Foundation • Aim: Disease control
Last updated Jun 26, 2026 15:08 UTC
-
Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
Internal radiation therapy shows promise in pilot study for multiple cancers
Disease control CompletedThis pilot study tested high dose rate brachytherapy, a type of internal radiation, in 43 patients with cervical, endometrial, esophageal, prostate, or biliary cancer. The goal was to see if the radiation implants could deliver the planned dose accurately. Participants received b…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 26, 2026 13:29 UTC
-
Esmya under the microscope: is Long-Term use safe for fibroids?
Disease control CompletedThis study followed over 1,500 women with moderate to severe uterine fibroids who were taking Esmya (ulipristal acetate) long-term. Researchers tracked side effects, especially those affecting the uterus, and how doctors prescribed the drug in everyday practice. The goal was to b…
Sponsor: PregLem SA • Aim: Disease control
Last updated Jun 26, 2026 13:15 UTC
-
New cancer drug EVT801 tested in humans for first time
Disease control CompletedThis early-stage trial tested an experimental drug called EVT801 in 32 adults with advanced solid tumours that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose to use in future studies. Participants took EVT801 cap…
Phase: PHASE1 • Sponsor: Kazia Therapeutics Limited • Aim: Disease control
Last updated Jun 26, 2026 13:12 UTC
-
Bag it up: new device aims to make fibroid surgery safer
Disease control CompletedThis study tested whether using a special bag during laparoscopic fibroid removal (myomectomy or hysterectomy) can prevent the spread of cells that might be cancerous. Forty-eight women were randomly assigned to have the procedure with or without the bag. Researchers then checked…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 26, 2026 12:48 UTC
-
New scan could reveal hidden cancer cells
Diagnosis CompletedThis early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
Pee test for cervical cancer? study checks if women like it
Diagnosis CompletedThis study looked at whether women would be willing to collect their own urine sample for cervical cancer screening instead of a traditional swab. 173 women aged 31-49 at a French hospital tried it and answered questions about their experience. The goal was to see how acceptable …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Could a simple pad replace invasive biopsies for uterine cancer?
Diagnosis CompletedThis study tested a special pad (PadKit™) worn for 4-6 hours to collect cells shed from the uterus. Researchers wanted to see if the pad could gather enough cells to tell the difference between normal tissue, precancerous changes, and cancer. 80 women scheduled for surgery (some …
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Could a 'Negative' HPV test miss warning signs? new study investigates
Diagnosis CompletedThis study looked at 45 patients whose HPV tests came back negative but had a late signal in the raw data. Researchers wanted to see if these late signals might actually indicate early cervical cell changes. By comparing different lab methods, they aim to improve how we interpret…
Sponsor: University Hospital, Brest • Aim: Diagnosis
Last updated Jun 27, 2026 12:03 UTC
-
New Self-Test could revolutionize cervical cancer screening
Diagnosis CompletedThis study tested a new way to screen for cervical cancer using samples women collect themselves at home. Researchers wanted to see if a test that looks at DNA changes in HPV could better identify who truly needs follow-up care. About 294 women participated, and the goal was to m…
Sponsor: George Washington University • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
Smarter screening: could a simple score reduce unnecessary biopsies?
Diagnosis CompletedThis study tested a new colposcopy method that uses a scoring system (Swede score) to better diagnose cervical precancer in women with abnormal screening results. Researchers enrolled 929 women referred for colposcopy to see if the scoring system could accurately identify precanc…
Sponsor: University of Aarhus • Aim: Diagnosis
Last updated Jun 27, 2026 09:03 UTC
-
Self-Sampling could boost cervical cancer screening in older women
Diagnosis CompletedThis study tested whether women aged 50 to 65 can collect their own samples for HPV testing to screen for cervical cancer. About 500 women in Cameroon participated. Those who tested positive for HPV then had a Pap smear and other exams to check for precancerous changes. The goal …
Sponsor: University Hospital, Geneva • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
New PET tracer aims to light up hidden infections
Diagnosis CompletedThis early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New pap smear method could spot cervical cancer earlier in egyptian women
Diagnosis CompletedThis study tested a liquid-based Pap smear (ThinPrep) to screen 984 Egyptian women aged 25–60 for early signs of cervical cancer during routine gynecology visits. The goal was to see if this method could detect abnormal cells more effectively than standard approaches. Results wil…
Sponsor: Kasr El Aini Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:00 UTC
-
New pap smear device aims to reduce pain and boost screening rates
Diagnosis CompletedThis study tested a new device called the Femscope Calm Collect Device for collecting cervical cells during cancer screening. The goal was to see if it could collect cells just as well as a traditional Pap smear but with less pain and discomfort. Thirteen healthy women aged 21-45…
Phase: NA • Sponsor: University of Michigan • Aim: Diagnosis
Last updated Jun 27, 2026 07:55 UTC
-
New radioactive tracer could sharpen cancer scans
Diagnosis CompletedThis early-phase trial tested a new radioactive imaging agent called 68Ga-NOTA-SNA002 in 17 adults with solid tumors. The agent was injected into a vein, and researchers checked its safety, how it spreads in the body, and how well it shows up on PET scans. The goal was to see if …
Phase: PHASE1 • Sponsor: SmartNuclide Biopharma • Aim: Diagnosis
Last updated Jun 26, 2026 18:18 UTC
-
Mail-Order HPV test could save lives in underscreened appalachian women
Diagnosis CompletedThis study tested whether offering at-home HPV self-testing kits can increase cervical cancer screening among women in Appalachia who are overdue for screening. Over 800 women from participating clinics were given either usual care or a self-testing kit along with information and…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 26, 2026 15:59 UTC
-
New radioactive tracer tested for cancer imaging in tiny early trial
Diagnosis CompletedThis early-phase trial tested a single injection of a radioactive imaging agent called 68Ga-LNC1007 in 8 adults (healthy volunteers and solid tumor patients). The goal was to check its safety, how it moves through the body, and how well it shows up on scans. The study is already …
Phase: PHASE1 • Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD. • Aim: Diagnosis
Last updated Jun 26, 2026 12:39 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase: PHASE2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
Culturally tailored program aims to boost cervical cancer screening in black women
Prevention CompletedThis study tests a program called 'Health is Wealth: A Cervical Health Program' designed to encourage cervical cancer screening among African American and Sub-Saharan African immigrant women. Participants attend a two-hour educational session and receive an HPV self-sampling kit …
Phase: NA • Sponsor: Adebola Adegboyega • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Phase: NA • Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Game changers: peer advocates aim to prevent cervical cancer in uganda
Prevention CompletedThis study tested a program called Game Changers for Cervical Cancer Prevention (GC-CCP) in Uganda. It trained women who had already been screened to encourage their friends and family to get screened too. The trial involved 936 participants and compared the program to usual care…
Phase: NA • Sponsor: RAND • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
Can the HPV vaccine stop cervical abnormalities from returning after surgery?
Prevention CompletedThis study looked at whether giving the Gardasil 9 HPV vaccine to women at the same time as surgery for abnormal cervical cells (CIN) can help clear the virus and prevent future infections. About 1,100 women aged 18-55 took part. The goal was to see if the vaccine reduces the cha…
Phase: PHASE3 • Sponsor: Imperial College London • Aim: Prevention
Last updated Jun 27, 2026 12:28 UTC
-
At-Home HPV test kits could boost cervical cancer screening in Hard-to-Reach women
Prevention CompletedThis study tested whether offering a vaginal self-sampling kit directly to women aged 50-65 who had not had a cervical smear in over three years would increase screening participation. Women received a kit to use at home and mail to a lab for HPV testing. The goal was to see how …
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
New screening strategy aims to prevent uterine cancer in High-Risk women
Prevention CompletedThis study tested a two-step screening process to find postmenopausal women at higher risk for endometrial cancer. Those identified as high-risk received a hormone challenge test and, if positive, standard care plus a lifestyle program. The goal was to see if this approach is pra…
Phase: PHASE4 • Sponsor: University of British Columbia • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
At-Home HPV test could save lives in underserved asian women
Prevention CompletedThis completed trial enrolled 797 Asian American women (Korean, Vietnamese, Chinese) aged 30-65 who were overdue for cervical cancer screening. All participants received community education and help scheduling a clinic screening. Half also got an HPV self-sampling kit to use at h…
Phase: NA • Sponsor: Fox Chase Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
At-Home HPV test could help underserved women skip the clinic
Prevention CompletedThis study tested whether mailing HPV self-test kits to women who are overdue for cervical cancer screening could increase participation. Over 2,400 underserved women in Texas were randomly assigned to receive a kit or standard phone reminders. The goal was to see if the at-home …
Phase: NA • Sponsor: Baylor College of Medicine • Aim: Prevention
Last updated Jun 26, 2026 13:41 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Phase: NA • Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Remote strength training aims to boost endometrial cancer survivorship in rural areas
Symptom relief CompletedThis study tests a 10-week, remotely supervised strength training program for endometrial cancer survivors living in rural or underserved areas. The goal is to see if the program is practical and helps improve physical function and quality of life. Participants exercise twice a w…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New drug may ease severe skin rashes in cancer patients
Symptom relief CompletedThis study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New nursing approach cuts clots and swelling after cervical cancer surgery
Symptom relief CompletedThis study tested whether a special nursing plan (called ERAS) could help women recover after surgery for cervical cancer. 160 women were split into two groups: one got the ERAS nursing plan, the other got standard care. The goal was to see if the ERAS plan could lower the risk o…
Phase: NA • Sponsor: People's Hospital of Xinjiang Uygur Autonomous Region • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Cancer Survivors' sex drive gets a boost: bupropion shows promise
Symptom relief CompletedThis study tested whether bupropion, a medication that affects brain chemicals, can improve low sexual desire in women who have had breast or gynecologic cancer. About 230 women took either bupropion or a placebo pill for 9 weeks. The main goal was to see if their self-reported s…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Vitamin cocktail may shrink fibroids, reduce surgery need
Symptom relief CompletedThis study tested a 3-month treatment with a combination of vitamin D, green tea extract (EGCG), vitamin B6, and D-Chiro-inositol in 108 women with uterine fibroids who were planning surgery. The goal was to see if the supplement could ease symptoms and possibly help some women a…
Phase: NA • Sponsor: Universita di Verona • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can a simple dilator boost sexual health after cancer treatment?
Symptom relief CompletedThis study looked at whether using a vaginal dilator for 12 weeks helps women who had brachytherapy for cervical cancer. Researchers measured sexual function, self-compassion, and quality of life in 80 participants at three time points. The goal was to see if this simple tool can…
Phase: NA • Sponsor: Istanbul Aydın University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
New study tests best method to cut bleeding in fibroid surgery
Symptom relief CompletedThis study looked at 120 women having open surgery for uterine fibroids to see which method best reduces bleeding. Doctors compared using a tourniquet, clamping the uterine artery, or no compression at all. The goal is to find the safest way to control blood loss and improve reco…
Phase: NA • Sponsor: Yuzuncu Yil University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Robot-Assisted hysterectomy shows promise in small trial
Symptom relief CompletedThis study tested the safety and effectiveness of the DEXTER robotic system in 52 patients having a hysterectomy (removal of the uterus) and related surgery for non-cancerous conditions. The main goals were to see if the robotic procedure could be completed without switching to o…
Sponsor: Distalmotion SA • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
New vaginal surgery technique may reduce pain after hysterectomy
Symptom relief CompletedThis study compared two types of minimally invasive hysterectomy: vNOTES (done through the vagina) and conventional laparoscopic hysterectomy (done through small belly cuts). About 90 women having hysterectomy for non-cancer reasons took part. The goal was to see which method cau…
Phase: NA • Sponsor: Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Walking your way through chemo: study tests if steps keep treatment on track
Symptom relief CompletedThis study tested whether a simple walking program, guided by a fitness tracker, could help cancer patients tolerate their chemoradiotherapy without missing treatments. 166 adults with brain, head and neck, lung, gastrointestinal, or cervical cancer participated. Patients were gi…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Can a nurse and an app improve life after gynecologic cancer?
Symptom relief CompletedThis study tested a new way to follow up with gynecologic cancer survivors. Instead of seeing a doctor every time, patients saw a nurse at every other visit and used a smartphone app to help manage their health. The goal was to see if this approach improved self-management skills…
Phase: NA • Sponsor: Sorlandet Hospital HF • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Acupuncture before surgery may steady blood pressure in hysterectomy patients
Symptom relief CompletedThis small pilot study looked at whether acupuncture given twice before surgery could help stabilize blood pressure in women having their uterus removed (total laparoscopic hysterectomy) for fibroids. Thirty-five adult patients received acupuncture before the operation, and resea…
Phase: NA • Sponsor: Ilsan Cha hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can pelvic PT help cancer survivors regain sexual health?
Symptom relief CompletedThis study looked at whether a 10-week pelvic physical therapy program is practical for gynecologic cancer survivors who have sexual problems. Twenty survivors were enrolled to see if they could stick with the program and if it improved their sexual function and quality of life. …
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can brain training ease 'Chemo Brain' in gynecologic cancer survivors?
Symptom relief CompletedThis study tested a home-based cognitive training program called BrainHQ in 60 women with gynecologic cancers who had memory or thinking problems after chemotherapy. Participants used the app for about 2.5 hours per week for 10 weeks. The goal was to see if the program was practi…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Could a common painkiller combo ease cancer treatment pain?
Symptom relief CompletedThis study tested whether adding ketoprofen to standard paracetamol (acetaminophen) can better control pain in patients receiving brachytherapy for cervical or upper airway/digestive tract cancers. Sixty-eight adults were randomly assigned to receive either paracetamol alone or p…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Phone therapy eases cancer Survivors' distress in rural areas
Symptom relief CompletedThis study tested a stepped-care telehealth program for cancer survivors living in rural areas who experience anxiety, depression, or sleep problems. Participants received either low-intensity check-ins or high-intensity phone therapy with a licensed therapist, depending on sympt…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Prehabilitation boosts pelvic floor recovery in cervical cancer patients
Symptom relief CompletedThis study tested a 4-week exercise program before surgery (prehabilitation) in 34 women with cervical cancer. The program included aerobic, resistance, and pelvic floor exercises. Results suggest it may improve pelvic floor strength and shorten hospital stays compared to standar…
Phase: NA • Sponsor: Saveetha University • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Acupuncture may help bladder function after cervical cancer surgery
Symptom relief CompletedThis study reviewed medical records of 73 women who had trouble emptying their bladder after cervical cancer surgery. Researchers compared two different sets of acupuncture points to see which worked better. The goal was to reduce leftover urine in the bladder and ease belly disc…
Sponsor: Lu Chao • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Nerve block eases Post-Surgery insomnia and anxiety in women
Symptom relief CompletedThis study tested whether a nerve block (stellate ganglion block) combined with standard anesthesia could help women with uterine fibroids sleep better and feel less anxious after laparoscopic surgery. 233 women aged 35-55 took part. Results aim to show if this approach reduces s…
Phase: NA • Sponsor: Xiaochen Ji • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Newer vaginal surgery for hysterectomy may be as safe as standard keyhole method
Symptom relief CompletedThis study compared two surgical techniques for removing the uterus (hysterectomy) due to non-cancerous conditions: the newer vNOTES method (done through the vagina) and standard laparoscopy (keyhole surgery). 145 women took part, and researchers tracked complications, pain, and …
Phase: NA • Sponsor: University Hospital, Clermont-Ferrand • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
New anesthesia drug tested for safer surgery in endometrial cancer patients
Symptom relief CompletedThis study tested whether oliceridine, a newer painkiller, is as safe and effective as the standard drug sufentanil for putting patients to sleep before gynecologic laparoscopic surgery. 120 women with endometrial cancer took part. Researchers monitored blood pressure and heart r…
Phase: NA • Sponsor: Tangshan Maternal and Child Health Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Could a common cholesterol drug protect cancer Patients' hearing?
Symptom relief CompletedThis study looked at whether taking statins (cholesterol-lowering drugs) can reduce hearing loss caused by platinum-based chemotherapy in people with solid tumors. 56 adults who were about to start chemotherapy took part. The goal was to see if statins could protect their ears fr…
Phase: PHASE1, PHASE2 • Sponsor: Minia University • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Talking through cancer: can couples therapy ease the emotional toll?
Symptom relief CompletedThis study tested a program that teaches couples communication skills when one partner has advanced cancer. About 440 patients and their partners took part, with half receiving the training and half getting general healthy living information. The goal was to see if the training c…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Shea butter and niacinamide cream may ease itching for immunotherapy patients
Symptom relief CompletedThis study tested whether using creams with niacinamide and shea butter can prevent or reduce skin itching in cancer patients receiving immunotherapy. 130 adults with solid tumors starting checkpoint inhibitor treatment were randomly assigned to use either the test cream or a con…
Phase: NA • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New pill aims to ease heavy periods from fibroids
Symptom relief CompletedThis Phase 2 trial tested an oral drug called DW4902 in 71 premenopausal women with uterine fibroids and heavy menstrual bleeding. Participants took either a placebo or one of three doses of DW4902 daily for 12 weeks. The main goal was to see if the drug could reduce bleeding to …
Phase: PHASE2 • Sponsor: Daewon Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Steroid injection during fibroid procedure may ease Post-Op pain
Symptom relief CompletedThis study tested whether giving an anti-inflammatory steroid directly into the uterine arteries during a non-surgical fibroid treatment can lessen pain, nausea, vomiting, and tiredness afterward. Forty-two women with symptomatic fibroids took part. The goal was to see if this si…
Phase: PHASE3 • Sponsor: University of Miami • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Numbing shots before fibroid surgery may ease Post-Op pain
Symptom relief CompletedThis study tested whether injecting the numbing drug ropivacaine into the belly and around a nerve cluster before surgery can lower pain after laparoscopic fibroid removal. 207 women having fibroid surgery were randomly assigned to get either ropivacaine or a placebo. The main go…
Phase: NA • Sponsor: Saint Petersburg State University, Russia • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
New pain block may reduce opioid use after hysterectomy
Symptom relief CompletedThis study compared two types of nerve blocks (TAP and TFP) to see which provides better pain relief after a hysterectomy. 77 women having the surgery received one of the blocks, and researchers measured their pain scores and how much opioid painkiller they needed. The goal was t…
Phase: NA • Sponsor: Hacettepe University • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Nerve block may cut opioid needs after hysterectomy
Symptom relief CompletedThis study tested whether a nerve block called the anterior quadratus lumborum block, given before surgery, can reduce pain and the need for opioids in women undergoing abdominal hysterectomy. 56 participants were randomly assigned to receive either the nerve block plus standard …
Phase: NA • Sponsor: Yuri Semenyuk Rivne Regional Clinical Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Supplements before fibroid surgery show promise in small study
Symptom relief CompletedThis pilot study tested whether taking a combination of EGCG (from green tea), vitamin D, and D-chiro-inositol for three months before hysteroscopic myomectomy improves surgical outcomes. 90 women with uterine fibroids were divided into two groups: one received the supplements be…
Sponsor: Centro di Ricerca Clinica Salentino • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
New drug combo cuts chemo nausea in half for gynecologic cancer patients
Symptom relief CompletedThis study tested whether adding the drug aprepitant to standard anti-nausea medicine helps women with gynecologic cancers (like ovarian or cervical cancer) who are getting chemotherapy. 143 women took part. The goal was to see if the extra drug could better prevent nausea and vo…
Phase: PHASE3 • Sponsor: Sichuan Cancer Hospital and Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
New pill could tame fibroid symptoms without surgery
Symptom relief CompletedThis study tested an oral drug called KLH-2109 in 89 premenopausal Japanese women with uterine fibroids who had heavy bleeding and pain. The goal was to see if the drug could reduce bleeding and pain better than a placebo. The trial was completed and may point to a new way to man…
Phase: PHASE3 • Sponsor: Kissei Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Exercise boosts heart health in endometrial cancer survivors
Symptom relief CompletedThis study looked at whether a 12-week program of aerobic and strength exercises could improve heart health and fitness in women who finished treatment for endometrial cancer. Thirty-three survivors in remission took part. They received exercise equipment and a Fitbit, and had he…
Phase: NA • Sponsor: Jess S. Gorzelitz • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Brain zaps boost balance in breast cancer survivors
Symptom relief CompletedThis pilot study tested whether a non-invasive brain stimulation technique called tDCS could improve balance and thinking in older women who had chemotherapy for breast cancer. 48 women aged 50-85 took part. The results will show if this approach can help with common side effects…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Can reiki ease cancer pain? small study says maybe
Symptom relief CompletedThis study tested whether Reiki, a relaxation therapy where a practitioner places hands on or near the body, could help cancer patients with symptoms like pain and fatigue. Ten adults with cancer who had at least three bothersome symptoms received up to six Reiki sessions. Resear…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Fitbit program helps cancer survivors get moving, study finds
Symptom relief CompletedThis study tested a physical activity program for breast and endometrial cancer survivors who were not getting enough exercise. Participants started with a Fitbit activity tracker linked to their electronic health record, and those who did not improve were offered extra support l…
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Targeted radiation shows promise for recurrent gynecologic cancers
Symptom relief CompletedThis early-phase study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 15 women whose ovarian or uterine cancer had come back in a limited area. The main goal was to find the safest dose and check for side effects. Researchers also looked a…
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Can a short video ease anxiety for cancer patients facing radiation?
Symptom relief CompletedThis study tested whether an educational video about brachytherapy (a type of internal radiation) helps women with cervical or uterine cancer feel more satisfied and less anxious. Eighty patients were randomly assigned to watch the video or receive standard consent only. Research…
Phase: NA • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
New online program eases Kids' cancer return to school
Symptom relief CompletedThis study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…
Phase: NA • Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
New study tests monthly day care for advanced cancer patients
Symptom relief CompletedThis study looked at whether monthly visits to a hospital day care that includes palliative care can improve quality of life for adults with advanced cancer. 144 patients with a life expectancy between 2 and 12 months took part. Researchers measured changes in quality of life, fa…
Phase: NA • Sponsor: Institut Curie • Aim: Symptom relief
Last updated Jun 26, 2026 18:50 UTC
-
Fiber pills may ease radiation side effects for pelvic cancer patients
Symptom relief CompletedThis completed phase 3 trial tested whether taking psyllium husk fiber capsules during pelvic radiation therapy could reduce gut inflammation and urgency symptoms. 354 adults with pelvic cancers (like rectal, prostate, or gynecological) took either fiber or placebo capsules daily…
Phase: PHASE3 • Sponsor: Sahlgrenska University Hospital • Aim: Symptom relief
Last updated Jun 26, 2026 15:22 UTC
-
Can a smartphone app and fitbit ease cancer treatment? new study says maybe.
Symptom relief CompletedThis study tested whether a smartphone app (HOPE or SMART) paired with a Fitbit could help women with recurrent gynecologic cancer manage symptoms and improve quality of life during chemotherapy. 102 women participated, using the app to track symptoms and receive advice, while we…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 26, 2026 14:54 UTC
-
Could a tiny ear device replace opioids after cancer surgery?
Symptom relief CompletedThis study tested a device that sends mild electrical pulses to the ear (called PENS) to see if it can reduce pain and the need for strong painkillers after surgery for endometrial or cervical cancer. 48 women who had open surgery took part. The goal was to find a safer, non-drug…
Phase: NA • Sponsor: DyAnsys, Inc. • Aim: Symptom relief
Last updated Jun 26, 2026 13:42 UTC
-
Enzyme-HPV link in cervical disease explored
Knowledge-focused CompletedThis study looked at how certain enzymes called matrix metalloproteinases (MMPs) and their inhibitors relate to human papillomavirus (HPV) in cervical dysplasia and cancer. Researchers collected tissue and cell samples from 216 women with different stages of cervical lesions. The…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Blood test may predict cancer spread in women
Knowledge-focused CompletedThis completed study looked at whether a simple blood test (liquid biopsy) can help track breast, ovarian, and endometrial cancers. Researchers analyzed circulating tumor cells in 150 women to see if these cells could predict the risk of cancer spreading or how well treatment wor…
Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can survivor stories get more people screened for cancer?
Knowledge-focused CompletedThis study tested whether a short video featuring cancer survivors and local leaders could encourage more people in rural Tamil Nadu to get screened for oral, breast, and cervical cancer. Over 1,200 adults aged 30-59 who had not been screened recently were randomly assigned to se…
Phase: NA • Sponsor: International Agency for Research on Cancer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to unlock secrets of immunotherapy skin reactions
Knowledge-focused CompletedThis study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study probes how pelvic cancer strains Couples' intimacy
Knowledge-focused CompletedThis study followed 40 women with cervical, uterine, or ovarian cancer to see how their relationship and sexual communication changed from diagnosis to 3 months after treatment. Participants filled out questionnaires about their sexual activity, desire, and discomfort. The goal w…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Study reveals why immunotherapy works differently in liver, lung, and brain tumors
Knowledge-focused CompletedThis study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…
Sponsor: Wenlong Zhong, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Nurse navigators boost cervical cancer screening in study
Knowledge-focused CompletedThis study tested whether a nurse navigation program—including education, counseling, and WhatsApp follow-up—could encourage more women aged 30-65 to get screened for cervical cancer. 80 women who were not regularly screened took part. The program aimed to improve their understan…
Phase: NA • Sponsor: TURKAN OZDAS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Proton therapy gets a daily Tune-Up in small pilot study
Knowledge-focused CompletedThis pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Stiffness check could boost fibroid treatment success
Knowledge-focused CompletedThis study looked at whether measuring the stiffness of uterine fibroids can help predict how well they respond to a non-invasive treatment called MR-HIFU. Forty women with symptomatic fibroids were enrolled. The goal was to improve patient selection so that only those likely to …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
AI learns to spot cancer pain from faces and voices
Knowledge-focused CompletedThis study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Faith-based workshops aim to boost cancer screening in muslim women
Knowledge-focused CompletedThis study tested whether a two-hour, peer-led workshop with religious messages could encourage Muslim women in North East England and Scotland to get screened for breast, bowel, and cervical cancer. 169 women aged 25-74 who were not up-to-date with all eligible screenings took p…
Phase: NA • Sponsor: University of Sunderland • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Massive cancer registry tracks genetic Testing's Real-World impact
Knowledge-focused CompletedThis completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
PET/CT scans may sharpen cancer Follow-Up decisions
Knowledge-focused CompletedThis study looked at whether a special PET/CT scan, done within two months after treatment, helps doctors make better decisions for patients with advanced cervical cancer. Researchers compared what doctors would decide without the scan versus with it. The study involved 40 patien…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New study aims to predict which fibroids respond best to Non-Invasive ultrasound treatment
Knowledge-focused CompletedThis study looked at 40 women with symptomatic uterine fibroids to understand why MR-guided focused ultrasound (HIFU) works better for some than others. Researchers used MRI and contrast-enhanced ultrasound to measure fibroid blood flow, stiffness, and other features before treat…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Embarrassment may be costing lives: study probes why women delay cancer checks
Knowledge-focused CompletedThis study interviewed 12 women diagnosed with gynaecological cancers (ovarian, womb, cervical, vulval, or vaginal) to understand what made them seek help or delay. Researchers focused on embarrassment and other barriers to early doctor visits. The goal is to use these insights t…
Sponsor: NHS Grampian • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Keyhole surgery blood loss study compares tying techniques
Knowledge-focused CompletedThis study looked at 60 women aged 35 to 60 who had a hysterectomy (removal of the uterus) through small cuts in the belly (laparoscopy). The goal was to compare two different methods of tying off the uterine arteries to see which one led to less blood loss during surgery. The re…
Phase: NA • Sponsor: Mostafa Bahaa • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
10-Year study checks if HPV test alone can replace pap smear
Knowledge-focused CompletedThis study follows over 1,700 women who previously took part in a cervical cancer screening trial. Researchers want to see if testing for HPV alone is as safe and effective as combining it with a Pap smear over 10 years. Participants provide a cervical sample for both tests, and …
Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New drug tracking study offers no cure, but key insights for future cancer treatments
Knowledge-focused CompletedThis study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a tiny radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to treat t…
Phase: PHASE1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New EHR tool aims to boost Heart-Health talks for cancer survivors
Knowledge-focused CompletedThis study tested a tool built into electronic health records that prompts doctors to discuss heart health with cancer survivors during routine visits. Researchers enrolled 645 survivors of breast, prostate, colorectal, endometrial, and lymphoma cancers across 12 clinics. The goa…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Nepal study tests whether fighting stigma gets more women screened for cervical cancer
Knowledge-focused CompletedThis study tested a program designed to reduce stigma around cervical cancer and increase screening among women in Nepal. Researchers enrolled 310 married women aged 30-60 from one municipality. The program included educational videos and group discussions. The goal was to see if…
Phase: NA • Sponsor: Kathmandu University School of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Routine BRCA testing for ovarian cancer patients proves feasible in irish study
Knowledge-focused CompletedThis study tested whether it is practical to routinely check ovarian cancer tumors for BRCA gene mutations in the clinic. Researchers enrolled 200 patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. They used blood and tumor samp…
Sponsor: Cancer Trials Ireland • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Scientists hunt for biomarkers to predict radiation damage
Knowledge-focused CompletedThis study analyzed blood, urine, and tissue samples from 273 adults with brain or lung cancer who were receiving radiation therapy. The goal was to find biological markers that could predict which patients are more likely to develop serious side effects from radiation, such as l…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Phase: NA • Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Could T-DXd outperform standard care for multiple HER2-Positive cancers? new study investigates
Knowledge-focused CompletedThis study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Fertility after fibroid embolization: new data from 46 women
Knowledge-focused CompletedThis study looked back at 46 women who had a procedure called uterine artery embolization to treat fibroids. The goal was to see how often women later had a baby and what pregnancy complications occurred. The researchers reviewed medical records from one hospital in France to gat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Full or empty bladder? study tests best way to protect organs during cervical cancer radiation
Knowledge-focused CompletedThis study looked at 22 women with cervical cancer to see if having an empty bladder (using a catheter) or a full bladder (filled with 120cc of fluid) is better during a type of internal radiation called brachytherapy. The goal was to find which method lowers the radiation dose t…
Phase: NA • Sponsor: Institut de Cancérologie de Lorraine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Robot vs. standard surgery: which is safer for Women's cancers?
Knowledge-focused CompletedThis study looked at 386 women with cervical, uterine, or ovarian cancer to compare standard laparoscopic surgery versus robot-assisted laparoscopic surgery. The goal was to see which approach causes fewer complications within six months after the operation. Researchers tracked s…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New PET-scan method may sharpen brachytherapy for cervical cancer
Knowledge-focused CompletedThis study explores whether using a PET-scan at the start of brachytherapy (internal radiation) is feasible for patients with locally advanced cervical cancer. Fourteen participants who have already received chemoradiation will undergo an extra PET-scan during brachytherapy and a…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Michigan study tests ways to boost genetic testing in cancer patients
Knowledge-focused CompletedThis study looked at whether a special website or coaching phone calls could help more people with a personal or family history of certain cancers get genetic testing. Over 800 participants were randomly assigned to one of these two methods or to standard care. The goal was to se…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Can adding radiation to immunotherapy help advanced cancer patients? new study explores safety and 'Abscopal' effects
Knowledge-focused CompletedThis study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Chatbot coaches cancer survivors on genetic testing
Knowledge-focused CompletedThis study tested a digital chatbot (called CATALYST) to help cancer survivors learn about genetic testing for inherited cancer risk. Fifty adults who had certain cancers (like breast, ovarian, or prostate) used the chatbot or received usual care. The goal was to see if the chatb…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New clinic aims to ease the journey for women cancer survivors
Knowledge-focused CompletedThis study tested whether a special survivorship clinic, combined with an app for reporting symptoms, is practical for women who have finished curative treatment for early-stage breast, cervical, or endometrial cancer. Two hundred women visited the clinic at the start and end of …
Phase: NA • Sponsor: University College Cork • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Custom 3D printed devices aim to improve cancer radiation delivery
Knowledge-focused CompletedThis study tested whether custom 3D printed applicators could improve radiation delivery in brachytherapy for gynecological cancers. Thirteen patients with cervical, uterine, vaginal, or vulvar cancer received MRI-guided treatment using these personalized tools. The goal was to s…
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New study tackles bone pain caused by chemo-boosting drug
Knowledge-focused CompletedThis study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New stitch tool tested in robot surgeries shows promise
Knowledge-focused CompletedThis study tested a special stitch device (STRATAFIX Spiral PDS Plus) used in robot-assisted surgeries for weight loss (sleeve gastrectomy) and hysterectomy. 161 adults took part. The main goal was to see how well it controlled bleeding after stitching. Doctors also rated how eas…
Sponsor: Ethicon, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Surgery's hidden toll: new study tracks quality of life in gynecologic cancer survivors
Knowledge-focused CompletedThis completed study followed 40 women who had standard surgery for gynecologic cancers (endometrial, cervical, ovarian, or fallopian tube). Researchers measured changes in quality of life and checked for lower limb lymphedema (leg swelling). The goal was to learn how surgery aff…
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Discarded tumor tissue yields clues for future brain cancer therapies
Knowledge-focused CompletedThis study looked at leftover tumor tissue and blood samples from 141 adults with glioblastoma or other solid tumors who were having surgery. The goal was to measure cell counts and viability to help scientists design better treatments for brain cancer and other solid tumors in t…
Sponsor: Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Study reveals metabolic changes in gynecologic cancer patients after treatment
Knowledge-focused CompletedThis study looked at how a single round of chemotherapy or immunotherapy changes the way the body uses energy and fats in women with gynecologic cancers. Researchers measured breathing and blood markers in 43 participants before and after treatment. The goal was to learn more abo…
Sponsor: University of Tennessee Graduate School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
DIY cervical cancer test boosts screening rates, study finds
Knowledge-focused CompletedThis study looked at whether giving women a self-collection kit for HPV testing at their family doctor's office would encourage more women to get screened for cervical cancer. The study involved 308 women aged 30-65 who were overdue for screening. Some women were offered the usua…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New cancer drug interaction study: will antibiotics or antifungals change its effects?
Knowledge-focused CompletedThis study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Talking women into HPV tests: study tests motivational interviews
Knowledge-focused CompletedThis study tested whether motivational interviews based on the Health Belief Model could increase HPV-DNA testing among women aged 30-45 who hadn't been tested in five years. Researchers gave 4 sessions of motivational interviewing and educational materials to one group, while a …
Phase: NA • Sponsor: Muazez küçükkaya • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Study reveals hidden risks of fibroid surgery
Knowledge-focused CompletedThis study looked back at the medical records of 293 women who had surgery to remove uterine fibroids (myomectomy). The goal was to find out how often a hysterectomy (removal of the uterus) was needed during the procedure and what complications occurred within 30 days after surge…
Sponsor: Ain Shams University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Robots vs. surgeons: which is better for hysterectomy?
Knowledge-focused CompletedThis study compared robot-assisted laparoscopy using the Senhance Surgical System to conventional laparoscopy for hysterectomy and other uterine surgeries. Researchers measured operating time, blood loss, and safety in 78 patients. The goal was to see if the robot offers advantag…
Sponsor: University Hospital Tuebingen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Study examines pregnancy after fibroid surgery
Knowledge-focused CompletedThis completed observational study looked at 150 women to see how different types of fibroid removal surgery (hysteroscopic, laparoscopic, or laparotomic) affect pregnancy outcomes. It compared women who had surgery with those who did not, and also looked at whether surgery durin…
Sponsor: Centro di Ricerca Clinica Salentino • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Cancer patients happier getting immunotherapy at home?
Knowledge-focused CompletedThis French study asked 49 cancer patients how they felt about switching from hospital to home-based immunotherapy. The goal was to see if home treatment improved their satisfaction with care. It was an observational study, meaning no new treatments were tested—just patient exper…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Scientists try out new tools to feel how hard tumors are
Knowledge-focused CompletedThis study tested two new methods to measure pressure and stiffness inside solid tumors in 27 patients. One method uses a thin catheter to measure pressure directly, and the other uses sound waves like an ultrasound to check stiffness. The goal was to see if these measurements co…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
New vaginal surgery may ease brain pressure during hysterectomy
Knowledge-focused CompletedThis study compared two types of hysterectomy surgery: vNOTES (done through the vagina) and TLH (done through small belly cuts). Researchers measured optic nerve sheath diameter, an indirect sign of brain pressure, in 66 women. The goal was to see if vNOTES causes less pressure o…
Phase: NA • Sponsor: Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Which nerve block combo best eases pain after gynecologic cancer surgery?
Knowledge-focused CompletedThis study looked at 94 patients who had major abdominal surgery for gynecologic cancers. Researchers compared pain relief from a standard nerve block (TAP block) alone versus combining it with another block (QLB or RSB). The goal was to see which approach reduced pain and opioid…
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
New surgical order may keep vagina longer after hysterectomy
Knowledge-focused CompletedThis study tested whether starting a hysterectomy by cutting the back of the vagina (posterior colpotomy first) helps keep the vagina longer compared to the usual method. Eighty women having a hysterectomy for non-cancer reasons took part. The main goal was to measure any differe…
Phase: NA • Sponsor: Cairo University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
How far should surgeons go? study tests lymph node removal in uterine cancer
Knowledge-focused CompletedThis study looked at 150 women with intermediate- or high-risk endometrial cancer who had surgery to remove the uterus and nearby lymph nodes. Researchers compared removing lymph nodes up to a higher level (near the kidney) versus a lower level (near the pelvis) to see which appr…
Phase: NA • Sponsor: Ahmed Aouf • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
2000 women studied to uncover hidden patterns in endometriosis
Knowledge-focused CompletedThis study analyzed 2000 women who had surgery for endometriosis to see if the lesions tend to appear more on the right or left side of the pelvis. By carefully recording the location of each lesion during surgery, researchers hope to learn more about how endometriosis develops. …
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Mailed self-test boosts cervical cancer screening in hard-to-reach women
Knowledge-focused CompletedThis study looked at two methods to help women who have not been screened for cervical cancer get tested. One group received a vaginal self-sampling kit in the mail, while the other was invited to visit their general practitioner. The goal was to see which approach leads more wom…
Phase: NA • Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Scientists probe muscle mysteries in cancer weight loss
Knowledge-focused CompletedThis completed study looked at how muscle energy use differs in women with ovarian or endometrial cancer who are losing weight, depending on their body mass index (BMI). Researchers took blood samples, muscle biopsies, and fat tissue from 70 women during surgery. The goal was to …
Phase: NA • Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Chemo's hidden toll: study probes life after endometrial cancer treatment
Knowledge-focused CompletedThis study looked at how chemotherapy impacts the quality of life of women treated for stage II or III endometrial cancer. Researchers asked 51 patients to fill out questionnaires about their physical, emotional, and social well-being at least two years after finishing treatment.…
Phase: NA • Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Less surgery may be safer for early cervical cancer patients
Knowledge-focused CompletedThis study looked at 267 women with early-stage cervical cancer to compare two surgical approaches: removing all pelvic lymph nodes versus removing only the sentinel (first) lymph node. The goal was to see which method causes fewer complications within 6 months after surgery. Res…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Chemo nausea still a problem despite standard care, study finds
Knowledge-focused CompletedThis study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Your iPhone could be your next cancer symptom tracker
Knowledge-focused CompletedThis study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Scientists unravel the mystery of menstrual cramps and pain relief
Knowledge-focused CompletedThis study looked at 183 women with menstrual pain to understand why it happens and how naproxen (a common painkiller) relieves it. Using MRI scans, researchers measured uterine activity, blood flow, and oxygen levels before and after taking naproxen or a placebo. The goal is to …
Phase: PHASE4 • Sponsor: Endeavor Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Question list boosts cancer Patients' confidence and reduces anxiety
Knowledge-focused CompletedThis study tested whether giving cancer patients a list of questions to ask their doctors helps them feel more empowered and less anxious. About 96 patients, along with nurses and doctors, took surveys and shared their experiences. The goal is to improve communication and make pa…
Phase: NA • Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Cancer patients may not need lifelong immunotherapy, study suggests
Knowledge-focused CompletedThis study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…
Phase: PHASE3 • Sponsor: Dan Zandberg • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Smart devices track cancer recovery at home
Knowledge-focused CompletedThis study tested whether using at-home monitoring devices (like a wristband pedometer, scale, and blood pressure cuff) can help improve care for cancer patients after they leave the hospital following surgery. 22 patients with various cancers participated. The goal was to see if…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Immunotherapy side effects under the microscope: new study monitors autoantibodies
Knowledge-focused CompletedThis completed study followed 183 cancer patients starting checkpoint inhibitor therapy to see how often they develop autoantibodies—proteins that can mistakenly attack the body's own tissues. Researchers collected blood samples to track changes in several types of autoantibodies…
Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Massive study reveals real cancer risk for HPV-Positive women with mild pap smears
Knowledge-focused CompletedThis study followed over 46,000 women in the Netherlands who tested positive for HPV and had mild abnormal Pap results. Researchers tracked how many developed cervical cancer within five years. The goal was to see if these women could safely have fewer follow-up tests, making scr…
Sponsor: Gynaecologisch Oncologisch Centrum Zuid • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
App vs. paper: which diary boosts cancer pill adherence?
Knowledge-focused CompletedThis study tested whether an electronic diary app helps cancer patients take their oral medications more consistently than a traditional paper diary. A total of 124 adults with solid tumors or blood cancers were randomly assigned to use either the app or a paper diary to track th…
Phase: NA • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Timing matters: when to first assess symptoms in UC treatment?
Knowledge-focused CompletedThis completed study from Xijing Hospital looked at 180 adults with mild-to-moderate ulcerative colitis starting 5-ASA therapy. Researchers compared checking symptoms at 4, 8, or 12 weeks to see which timing best predicted treatment success at 48 weeks. The goal was to help docto…
Sponsor: Xijing Hospital of Digestive Diseases • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Blood mineral levels may differ in women's reproductive diseases
Knowledge-focused CompletedThis study measured 14 trace elements in blood samples from 40 women with endometriosis, ovarian cancer, endometrial cancer, or healthy controls. Researchers wanted to see if levels of elements like iron, selenium, or lead differ between these groups. The goal is to find clues th…
Phase: NA • Sponsor: Cumhuriyet University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New study sheds light on leg swelling after cancer surgery
Knowledge-focused CompletedThis study looked at 111 people who had surgery for early-stage cervical or vulvar cancer to find out how many develop lower leg swelling (lymphedema). Researchers used a questionnaire to gather information, not to test any new treatment. The goal is to better identify who is at …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Cancer patients with COVID: do early antiviral drugs help?
Knowledge-focused CompletedThis completed study looked at how well early COVID-19 antiviral therapies work in cancer patients. Researchers tracked 112 patients with solid tumors who received these treatments to see how many needed hospitalization within 14 days. The goal is to fill knowledge gaps and impro…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Taiwan study reveals HER2 rates in Hard-to-Treat gynecologic cancers
Knowledge-focused CompletedThis study looked at medical records from 509 adults in Taiwan to find out how often advanced cervical, endometrial, and ovarian cancers have a specific marker called HER2 IHC 3+. Researchers also described the patients' health details to better understand who might benefit from …
Sponsor: Daiichi Sankyo • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Can a lifestyle program help endometrial cancer survivors stay healthier?
Knowledge-focused CompletedThis study tested a group-based program to help endometrial cancer survivors adopt healthier habits. The goal was to lower their risk of other health problems like heart disease and diabetes. Twenty-three survivors who had finished cancer treatment took part in online learning an…
Phase: NA • Sponsor: University of Virginia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Gene-Based dosing study aims to make cancer drug safer
Knowledge-focused CompletedThis early-phase study tested the safety and drug levels of belinostat in 17 patients with advanced solid tumors or blood cancers that had not responded to prior treatments. Researchers grouped patients by their UGT1A1 gene type to see if genetic differences affect how the drug i…
Phase: PHASE1 • Sponsor: Acrotech Biopharma Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Exercise before surgery may slow cancer growth
Knowledge-focused CompletedThis study looked at whether high-intensity interval training (HIIT) — short, intense exercise sessions — could have anti-cancer effects in women with endometrial cancer. Thirty women did 4 to 6 HIIT sessions before their scheduled surgery. Researchers then checked tissue samples…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
HPV Vaccine's Long-Term power tested in rwandan women
Knowledge-focused CompletedThis completed study looked at how well the HPV vaccine protects against HPV infections over time in over 3,000 Rwandan women aged 18-28, some living with HIV and some without. Researchers collected blood, oral, and other samples to measure vaccine effectiveness and long-term ant…
Sponsor: Montefiore Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Should all young cancer patients get genetic testing? study investigates
Knowledge-focused CompletedThis study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …
Phase: NA • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Universal DNA screening in endometrial cancer reveals hidden genetic risks
Knowledge-focused CompletedThis study tested over 1,000 women with endometrial cancer for DNA repair problems that can be inherited (Lynch syndrome). By analyzing tumor DNA, researchers aimed to personalize cancer treatment and identify family members who might also be at risk. The goal was to improve care…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
New dye technique may help surgeons spot hidden cancer spread
Knowledge-focused CompletedThis study tested a modified method for injecting a green dye (indocyanine green) to help surgeons see lymph nodes during robotic surgery for early-stage endometrial cancer. The new approach injects the dye until the lymphatic channels are visible in real time, aiming to improve …
Phase: NA • Sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
New study aims to boost cancer screening among american indians
Knowledge-focused CompletedThis study worked with American Indian communities in New Mexico to find better ways to encourage screening for breast, colon, and cervical cancers. Over 500 adults took part in focus groups, surveys, and pilot programs. The goal was to understand barriers and test simple educati…
Phase: NA • Sponsor: New Mexico Cancer Research Alliance • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Fibroid location linked to changes in uterine blood flow
Knowledge-focused CompletedThis study looked at how the location of uterine fibroids affects blood flow in the uterine artery. Researchers used ultrasound to measure blood flow in 185 women with fibroids and compared results based on fibroid location. They found that fibroids located within the uterine mus…
Sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Drug interaction study tests liver enzyme effects on cancer treatment
Knowledge-focused CompletedThis study looked at how bosentan, a drug that affects liver enzymes, changes the levels of the cancer drug lurbinectedin in the blood. Eleven adults with advanced solid tumors received lurbinectedin alone and with bosentan. The goal was to see if bosentan alters how the body pro…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:46 UTC
-
New registry aims to sharpen use of precision radiation for cancer
Knowledge-focused CompletedThis study created a registry of 149 cancer patients who received a precise type of radiation called SBRT. The goal was to track how doctors use this treatment in four different situations: for cancer that has spread to a few spots, after chemotherapy, before starting chemotherap…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:50 UTC
-
New program tackles stigma to get more women with HIV screened for cervical cancer
Knowledge-focused CompletedThis study tested a program called Elimisha HPV, designed to reduce stigma and increase cervical cancer screening among women living with HIV in Kenya. The program included simple educational scripts, a video addressing fears, and peer support. Nearly 1,000 women participated, an…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:41 UTC
-
New drug interaction study aims to make future treatments safer
Knowledge-focused CompletedThis completed phase 1 study tested how SHR7280, a drug being developed for endometriosis and uterine fibroids, affects the way the body processes six other common drugs. Twenty healthy men took SHR7280 along with midazolam, warfarin, omeprazole, digoxin, and rosuvastatin to see …
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:33 UTC
-
Surgeons try High-Tech goggles to spot hidden tumors during keyhole surgery
Knowledge-focused CompletedThis completed study tested whether augmented reality (AR) can help surgeons during laparoscopic surgery for uterine fibroids or adenomyosis. AR overlays images from pre-surgery scans onto the live video feed, potentially making it easier to see and remove benign tumors. Forty pa…
Phase: NA • Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:26 UTC
-
Real-World data on HydroPearl embolization through the wrist
Knowledge-focused CompletedThis completed registry study collected real-world data on 99 patients receiving HydroPearl microspheres to block blood flow to conditions like uterine fibroids, arteriovenous malformations, hypervascular tumors, and benign prostatic hyperplasia. The procedure was done through th…
Sponsor: Terumo Medical Corporation • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:23 UTC
-
Study reveals hidden toll of chemo: taste loss and muscle wasting in gynecologic cancer patients
Knowledge-focused CompletedThis study followed 102 women with ovarian, fallopian tube, or endometrial cancer through six cycles of standard chemotherapy (carboplatin and paclitaxel). Researchers measured taste changes, muscle loss, and nutritional decline at the start, halfway, and end of treatment. The go…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:47 UTC
-
Small study tests drug interaction in advanced cancer patients
Knowledge-focused CompletedThis Phase 1 study looked at how the antifungal drug itraconazole affects the levels of the cancer drug lurbinectedin in 14 patients with advanced solid tumors. The goal was to understand potential drug interactions, not to treat the cancer. Results may guide future dosing and sa…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:50 UTC